Spravato is a prescription nasal spray medication approved for adults with treatment-resistant depression, and it contains esketamine. Because it is administered under medical supervision, it provides a unique approach to managing depressive symptoms. Clinical trials have studied its effects in specific populations. Here is more information about the efficacy of Spravato treatment:
Providing Rapid Delivery
Spravato is administered as a nasal spray, and this allows for quick absorption into the bloodstream. Since this medication is inhaled, it works faster than oral medications, which must first pass through the digestive system. The medication reaches the brain rapidly. Healthcare providers monitor patients for about two hours after administration. This observation period is a standard part of the treatment protocol.
Patients use the nasal spray device under medical supervision. After a healthcare professional shows you how to use it, you can self-administer the spray in a certified medical office. The process is direct, but it must happen in a specific setting.
Relieving Short-term Symptoms
Clinical studies investigate Spravato’s impact on depressive symptoms over short periods. One showed short-term symptom relief for some participants when used with an oral antidepressant. These short-term results are one aspect of the treatment’s profile.
Long-term studies also offer information on maintaining symptom relief. After a treatment period, some patients showed improvement with Spravato. Researchers track their progress over time, so they can gather data on sustained effects. These longer trials provide a broader view of the treatment process. Individual results will vary based on many personal factors.
The studies may measure the effectiveness of the drug for depression. While patients take the medication, they are monitored. Some main goals include:
- Observing changes in symptom severity.
- Tracking the time to a potential relapse of depressive symptoms.
- Assessing overall patient functioning.
Producing Antidepressant Effects
Esketamine, the active ingredient in Spravato, works differently from many common antidepressants. It targets the NMDA receptor in the brain, which is part of the glutamate pathway. This action may help restore synaptic connections between brain cells. Restoring these connections may lead to an improvement in mood.
The response to this treatment is individual. Some people may experience changes in their symptoms, while others may not. The medication is prescribed alongside a daily oral antidepressant, and it is not a standalone treatment. This combination approach was a key element of the clinical trials. The interaction between Spravato and the oral antidepressant contributes to the overall effect.
Requiring Multiple Sessions
Professionals typically administer Spravato treatment in cycles. The initial phase involves more frequent sessions, and you attend sessions more frequently during the first month. This structured beginning is the first phase.
Following the first month, the treatment frequency typically decreases. This next stage is the maintenance phase, and it is adjusted to your needs. You and your healthcare provider will determine the schedule. Sessions might be once a week or every two weeks. The number of sessions required varies from person to person. Ongoing evaluation helps guide the treatment plan.
Schedule Spravato Treatment Sessions
Clinical trials provide a framework for understanding how Spravato works for some individuals. The treatment involves a specific process, from its rapid delivery system to its multi-session schedule. If you are exploring options for treatment-resistant depression, speaking with a professional is a good next step. Contact a clinic today to learn more about the process and schedule a consultation.
